General
Pfizer’s COVID vaccine success is worth an extra $14 billion to the US pharma giant
The success of its COVID vaccine, and the challenges faced by some of its rivals, look set to earn US pharmaceutical giant Pfizer at least an extra $US11 billion ($14.2 billion) in revenue this year.
Key points:
- Pfizer has raised its 2021 revenue forecasts for COVID vaccine sales by 73 per cent
- Click here to view the original article.
Continue Reading
-
Noosa News24 hours agoTayla Harris stars as Melbourne defeats Essendon by 14 points
-
Business14 hours agoBell Potter names the best ASX shares to buy in October
-
Noosa News18 hours ago28 years later: Grim reality for single house hunters revealed
-
Noosa News13 hours agoDangerous driving charges, Maroochydore – Sunshine Coast